{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-051551","form_type":"8-K","ticker":"ZBH","cik":"0001136869","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.417739+00:00","generated_at":"2026-06-02T23:55:40.004244+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zimmer Biomet Q1 net sales $1.889B (+3.2%); adj. EPS $1.94; reiterates FY guidance","bullets":["Net sales $1.889B, up 3.2% reported and 4.4% constant currency; GAAP diluted EPS $0.84, adjusted $1.94.","Knees $788.1M (+3.4%), Hips $491.2M (-0.3%), S.E.T. $452.6M (+4.4%).","Reiterates FY2024 guidance: constant currency revenue growth 5-6%, adjusted EBITDA $8.00-$8.15 EPS.","FDA 510(k) clearance for ROSA Shoulder System (first robotic shoulder assist) and Z1 Femoral Hip Stem."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-051551","json":"https://secwatch.observer/filing/0000950170-24-051551.json","markdown":"https://secwatch.observer/filing/0000950170-24-051551.md","text":"https://secwatch.observer/filing/0000950170-24-051551.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1136869/000095017024051551/0000950170-24-051551-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1136869/000095017024051551/zbh-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T23:55:40.004244+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2d089881f0adedb967c22378ddfaba2b005eebef","claim":"ZIMMER BIOMET HOLDINGS, INC. updated its full-year 2024 guidance (reaffirmed).","evidence_excerpt":"The Company is reiterating its current full-year 2024 financial guidance. Projected Year Ending December 31, 2024 2024 Reported Revenue Change 4.5% - 5.5% Foreign Currency Exchange Impact (0.5)% 2024 Constant Currency Revenue Change 5.0% - 6.0% Adjusted Diluted EPS (1) $8.00 - $8.15","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1136869/000095017024051551/0000950170-24-051551-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2024"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"95667f662e27ea0ac28078c273e3fe0661ee0464","claim":"ZIMMER BIOMET HOLDINGS, INC. reported quarter ended March 31, 2024 results: revenue $1.889 billion, net income $172.4 million, EPS $0.84.","evidence_excerpt":"The Company reported first quarter net sales of $1.889 billion, an increase of 3.2% over the prior year period, and an increase of 4.4% on a constant currency 1 basis. Net earnings for the first quarter were $172.4 million, or $399.7 million on an adjusted 1 basis. Diluted earnings per share were $0.84 for the first quarter, and adjusted 1 diluted earnings per share were $1.94.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1136869/000095017024051551/0000950170-24-051551-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2024"},{"label":"Revenue","value":"$1.889 billion"},{"label":"Net income","value":"$172.4 million"},{"label":"EPS","value":"$0.84"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}